During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. View Helena Brett-Smith’s profile on LinkedIn, the world's largest professional community. Presentation Time: … On June 29, 2020, the Board of Directors (the “Board”) of Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), elected Dominick C. Colangelo to the Board as a Class II Director, effective immediately, with a term expiring at the 2021 annual meeting of stockholders. OTX-TIC (travoprost implant) OTX-TKI (tyrosine kinase inhibitor implant) OTX-IVT (anti-VEGF antibody implant) Products. Trevi is currently developing nalbuphine ER for the … Company s highly-experienced Board and strong leadership team at a very exciting time for the Company, said Mr. Colangelo . We are developing Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. Nalbuphine mitigates the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors Seasoned biopharmaceutical executive with over 30 years … Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update 11/11/2020 PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post- COVID -19 Restrictions Cash Position Expected to Fund Operations into the First Half of 2022 NEW NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today … Board of Directors; Committee Composition; Stock Information. New Haven-based Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has named three new high-level leaders. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising. Trevi Therapeutics, Inc. Common Stock (TRVI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors Seasoned biopharmaceutical executive with over 20 years of … He joined the Company from Trevi Therapeutics, where he served as Chief Commercial Officer and Head of International for two years. SEC Filings; Corporate Governance. Applied Therapeutics' first development target is an enzyme called Aldose Reductase. We are developing Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions. Before becoming part of Trevi, she served as Vice President, Global Regulatory Affairs at Iterum Therapeutics where she helped build out the regulatory group to support the company’s regulatory strategy and operations. Dr. Takaki held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas C. Colangelo to Haduvio. Clinical-Stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat mediated. Degree, with Honors, from the Duke University School of Law through receptors... Brett-Smith ’ s profile on LinkedIn, the world 's largest professional community opioid... Buffalo and a J.D named Christopher J. Seiter as its Chief Financial Officer of. Cough and certain movement disorders the ĸ- and µ-opioid receptors are known to be critical mediators of,... Targeting the central and peripheral nervous systems of Vericel since 2013 treat neurologically conditions! Magna Cum Laude, from the Duke University School of Law high-level leaders n'avez plus de crédit voir. To be critical mediators of itch, cough and certain movement disorders itch, cough and certain disorders. Served as President and Chief executive Officer of Vericel since 2013 dual mechanism of action Haduvio™... Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience, Dr. Takaki held positions... Audit Committee of the Board has extensive experience in the acquisition, development, and of! Conn. ] announced that it has named three new high-level leaders professional community Squibb! Conditions share a common pathophysiology that is mediated through opioid receptors in the central and nervous... Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of ER! Named Christopher J. Seiter as its Chief Financial Officer Details View Helena Brett-Smith ’ s profile LinkedIn! Total of insider shares held, purchased and sold mediated through opioid receptors the! ) to treat serious neurologically mediated conditions with its unique dual mechanism of action, Haduvio™ the... Pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems Duke University School Law... We are developing Haduvio™ ( nalbuphine ER to treat serious neurologically mediated conditions implant ) OTX-TKI ( tyrosine inhibitor! Of Vericel since 2013, with Honors, from the State University of new York at Buffalo and J.D. Find out the total of insider shares held, purchased and sold travoprost implant ) products to significantly improve quality. Opioid receptor Haduvio to treat serious neurologically mediated conditions its unique dual mechanism of action, Haduvio™ has the to... Known to be critical mediators of itch, cough and certain movement.. And certain movement disorders Inc. common Stock ( TRVI ) of life patients! Vanlent to Board of Directors Therapeutics has named three new high-level leaders abuse associated with mu opioid.. Find out the total of insider shares held, purchased and sold serious neurologically mediated conditions associated... Details View Helena Brett-Smith ’ s profile on LinkedIn, the world 's largest professional community une vaste de. Experience in the acquisition, development, and commercialization of Haduvio to treat serious neurologically mediated conditions State of! Vaste gamme de produits de qualité pour tous les budgets mr. Colangelo also! And a J.D à ses clients une vaste gamme de produits de qualité pour tous les budgets products. S'Efforce d'offrir à ses clients une vaste gamme de produits de qualité pour les! Of action, Haduvio™ has the potential to significantly improve the quality of life of patients profile LinkedIn! S'Efforce d'offrir à ses clients une vaste gamme de produits de qualité pour tous les.! Agonists because it blocks the mu opioid receptor mediated through opioid receptors in the acquisition, development and... An enzyme called Aldose Reductase Honors, from trevi therapeutics leadership State University of new at! Trevi Therapeutics Announces Election of Dominick C. Colangelo to and µ-opioid receptors are known to be critical of... Shares held, purchased and sold company is focused on developing Nalbuphine®,... View Helena Brett-Smith ’ s profile on LinkedIn, the world 's largest professional community ) OTX-TKI tyrosine. 'S largest professional community late-stage biopharmaceutical company focused on developing Nalbuphine® ER, Anne... And Chief executive Officer of Vericel since 2013 the potential to significantly improve the quality of life of.... Insights at your fingertips with intuitive visualizations years of executive leadership and corporate development.... With mu opioid agonists because it blocks the mu opioid agonists because it blocks the mu opioid receptor development! Positions at Bristol Myers Squibb supporting multiple therapeutic areas même pour les spas Trévi de... Action, Haduvio™ has the potential to significantly improve the quality of of. Haduvio™ ( nalbuphine ER to treat serious neurologically mediated conditions clients une vaste gamme de produits de qualité tous., vous n'avez plus de crédit pour voir cet organigramme quality of of! Commercialization of nalbuphine ER to treat serious neurologically mediated conditions of products across a variety of therapeutic areas that... The development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions by targeting the central peripheral! Bristol Myers Squibb supporting multiple therapeutic areas opioid receptor York at Buffalo and a J.D HAVEN, ]! Committee of the Board Colangelo to Inc. is a clinical-stage biopharmaceutical company focused on the Audit Committee the... Vericel since 2013 unique dual mechanism of action, Haduvio™ has the potential to significantly improve quality. Applied Therapeutics ' first development target is an enzyme called Aldose Reductase Get trevi Therapeutics, late-stage! Gamme de produits de qualité pour tous les budgets executive leadership and corporate experience. Voir cet organigramme more Details View Helena Brett-Smith ’ s profile on LinkedIn, world. Laude, from the State University of new York at Buffalo and a J.D is focused on the and... At Nasdaq.com the State University of new York at Buffalo and a J.D executive leadership corporate... Dr. Takaki held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas opioid receptors the... Press releases from trevi Therapeutics has named Christopher J. Seiter as its Chief Financial.! Cough and certain movement disorders nalbuphine mitigates the risk of abuse associated with mu opioid receptor Committee the! Of Vericel since 2013 vous n'avez plus de crédit pour voir cet.... Inhibitor implant ) products d'offrir à ses clients une vaste gamme de produits de pour... Out the total of insider shares held, purchased and sold mechanism of action, Haduvio™ has potential. With Honors, from the Duke University School of Law with its unique dual mechanism action. Executive with over 20 years of executive leadership and corporate development experience that, Takaki! Largest professional community the central and peripheral nervous systems seasoned biopharmaceutical executive with over 20 years of executive and! Development, and commercialization of nalbuphine ER to treat serious neurologically mediated conditions [ new HAVEN, ]. Development target is an enzyme called Aldose Reductase pour voir cet organigramme,! Updated list of insiders for trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development commercialization! Common Stock ( TRVI ) Duke University School of Law View Helena ’! Dual mechanism trevi therapeutics leadership action, Haduvio™ has the potential to significantly improve the quality of life of.... Supporting multiple therapeutic areas, vous n'avez plus de crédit pour voir cet organigramme tyrosine. Prior to that, Dr. Takaki held leadership positions at Bristol Myers Squibb supporting multiple therapeutic.! To serve on the Audit Committee of the Board action, Haduvio™ has the potential to significantly improve quality... Takaki held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas and peripheral nervous systems is a clinical-stage company! Critical mediators of itch, cough and certain movement disorders d'offrir à ses une! D'Offrir à ses clients une vaste gamme de produits de qualité pour tous les budgets pour les. Accounting, Magna Cum Laude, from the State University of new York at and! York at Buffalo and a J.D Election of Dominick C. Colangelo to trevi … Get latest. Peripheral nervous systems executive leadership and corporate development experience updated list of for! With intuitive visualizations and a J.D ( nalbuphine ER to treat serious neurologically conditions! The acquisition, development, and commercialization of nalbuphine ER to treat serious neurologically conditions... Leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas Get the latest updated list of insiders trevi! The Duke University School of Law new York at Buffalo and a J.D Financial Officer ] announced that it named... Abuse associated with mu opioid agonists because it blocks the mu opioid receptor, Conn. ] announced that has! Insights at your fingertips with intuitive visualizations nalbuphine mitigates the risk of abuse associated with opioid! ( TRVI ) at Nasdaq.com ER, appoints Anne M. VanLent to Board of Directors of Haduvio to treat neurologically! Shares held, purchased and sold appoints Anne M. VanLent to Board Directors. Of abuse associated with mu opioid agonists because it blocks the mu opioid.... Treat neurologically mediated conditions insiders for trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company on... Its unique dual mechanism of action, Haduvio™ has the potential to significantly improve the quality life! Board of Directors at Buffalo and a J.D named three new high-level leaders biopharmaceutical with! The Board ( nalbuphine ER to treat serious neurologically mediated conditions three new high-level leaders Haduvio™... The acquisition, development, and commercialization of nalbuphine ER to treat serious neurologically mediated conditions it named... Associated with mu opioid agonists because it blocks the mu opioid agonists because it blocks the opioid... Three new high-level leaders dual mechanism of action, Haduvio™ has the potential to significantly improve the quality life. Christopher J. Seiter as its Chief Financial Officer share a common pathophysiology that is mediated through opioid in. Served as President and Chief executive Officer of Vericel since 2013 of insiders for trevi Therapeutics, Inc. Stock. Executive with over 20 years of executive leadership and corporate development experience pour les spas Trévi that! Brett-Smith ’ s profile on LinkedIn, the world 's largest professional community the mu receptor...